Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
Related Tickers: APVO
TL;DR
APVO filed an 8-K, check for updates.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on September 4, 2025, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.
Why It Matters
This filing indicates that Aptevo Therapeutics Inc. is making a regulatory submission to the SEC, which could contain important updates for investors.
Risk Assessment
Risk Level: low — The filing is a routine regulatory submission and does not disclose any new material events or financial information that would inherently increase risk.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- September 04, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of September 4, 2025.
On what date was this 8-K filing reported?
The date of the report, and the date of the earliest event reported, is September 04, 2025.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The address of the Principal Executive Offices is 2401 4th Avenue Suite 1050, Seattle, Washington, 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
What is the IRS Employer Identification Number for Aptevo Therapeutics Inc.?
The IRS Employer Identification Number for Aptevo Therapeutics Inc. is 81-1567056.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-04 16:19:47
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20250904.htm (8-K) — 44KB
- apvo-ex99_1.htm (EX-99.1) — 31KB
- img237228349_0.jpg (GRAPHIC) — 9KB
- 0001671584-25-000005.txt ( ) — 198KB
- apvo-20250904.xsd (EX-101.SCH) — 24KB
- apvo-20250904_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 4, 2025, Aptevo Therapeutics Inc. (the "Company") issued a press release announcing expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451 for prostate cancer and multiple additional solid tumor types with significant unmet needs. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press release of Aptevo Therapeutics Inc. dated September 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: September 4, 2025 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer